Amarin Corp PLC News - AMRN

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Amarin Announces Two Upcoming Investor Events

-- Company to Report Third Quarter 2024 Financial Results Wednesday, October 30 –- -- Amarin to Hold Virtual...

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc...

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

-- Cash Position of $307 Million Provides Stable and Strong Capital Foundation –-- Total Net Revenue of $68...

Form 8-K - Current report

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the...

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today...

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular...

Form 8-K - Current report

Amarin Board of Directors Announces CEO Transition

-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to...

Tatsumaki 1 hour ago

And definitely not before we need to get the SP above a buck.
Who says this ticker has to stay listed?

👍️0

Number sleven 2 hours ago

JRoon, If you wouldn't mind, explain your position in detail. I only ask because you stated it as an an absolute.
Sleven,

👍️0

rosemountbomber 2 hours ago

I did that on two previous occasions thinking that the stock price was at a low point. Needless to say those didn’t work out very well for me, but to be fair, we only have 60 cents more to lose so you are probably right.

👍️0

Jasbg 3 hours ago

As I said earlier - Amarin has cost me the value of now 6 new Tesla 3 electric cars !

Actually the KM period is what I blame myself the most !

PS were at $ 6.63 - when he took over - but has fallen like a rock ever since.
-------------------------------------

Will we recover (partly / with profit) from this - that is as uncertain as who will be new President in US :)

👍️0

JRoon71 3 hours ago

Seve, you need a drink

👍️0

seve333 4 hours ago

If they do a reverse split they may as may fold up shop. A reverse split is nothing more than an invitation to shorts to destroy what little value is left in a stock price. And I mean unless denner is shorting the crap out of this his shares would also take a tremendous hit in a reverse split. I doubt the company would ever recover form it as most do not. Why would you do a reverse split on a 100 milllion dollar investement when you could actually do a buyback instead? The buyback is probably all they got to get it over a buck because the non usa sales are moving far too slow to make a difference. I dont recall when they have until but I thought it was May. If they cannot get it over a buck jn 7 moths then they are really really bad at this.

For anyone with significant AMRN shares in their IRA, now would be an ideal time to do a Roth conversion on those shares.

👍️0

JRoon71 6 hours ago

Shado, there is nothing from a legal perspective that is going to change anything in the next few years. And definitely not before we need to get the SP above a buck.

👍️0

Number sleven 6 hours ago

Shadolane, What's the time frame?
Sleven,

👍️0

shadolane 6 hours ago

Unless something significant happens in the litigation arena a reverse split may be the only way to salvage the pps from a compliance perspective within the time frame that Amarin has.

I doubt sales in other markets or studies for other uses will intervene in the near term.

We've encountered significant negative effects since the largest one......the Du decision.

And some of us may not be able to survive long enough to see how this all turns out.

IMO

👍️0

Nukemtiltheyglow 7 hours ago

xblkbk, are you of retirement age?

👍️0

JRoon71 8 hours ago

Wow! As a follow up to this post:
---------------------------------------------------------------------------

I just checked and it shows $98.40 for 30 day supply.

One thing that is frustrating is when I put “Vascepa” in the search bar, it comes back with:
Vascepa (generic)
Vascepa (brand-name)
icosapent ethyl (generic Vascepa)

---------------------------------------------------------------

I later saw that this came up when I selected Vascepa (generic):

So basically, when I selected "generic Vascepa", a pop-up box came up and told me that I could find BRANDED Vascepa for cheaper.

But then I also saw this description under generic Vascepa:
About generic Vascepa
Vascepa (icosapent ethyl) is used to reduce cardiovascular risk and treat high triglyceride levels.

👍️0

JRoon71 9 hours ago

I just checked and it shows $98.40 for 30 day supply.

One thing that is frustrating is when I put “Vascepa” in the search bar, it comes back with:
Vascepa (generic)
Vascepa (brand-name)
icosapent ethyl (generic Vascepa)

Exactly as typed, and in that order

👍️0

rosemountbomber 9 hours ago

North, I wonder if it is possible that this discounted price on GoodRx has only been put into effect very recently and was not in effect 30 days ago.

👍️0

north40000 10 hours ago

That exclusive “discount” did not work or was “not available” when I refilled a 90 day brand Vascepa prescription at CVS a month ago, as previously reported. We will try again in another supply 2 months at the same or different pharmacy. Thanks for the news.

That suit filed by Express Scripts and CVS/Caremark against FTC in Missouri is meritless as far as I’m concerned. My usual co-pay cost of $9 or $15 for a 3- month Vascepa supply had disappeared as of 7/01, replaced by over a $1000 cash payment even with a GoodRX coupon.

👍️0

Birdbrain Ideas 11 hours ago

That's great news. Makes sense that Amarin probably will be in better position to adjust U.S. prices once it is finished negotiating most of its deals in Europe.

👍️0

Meowza 11 hours ago

Europe worth more than Italy, France and Germany combined 🙃

👍️0

Meowza 11 hours ago

We have already been creamed under denner That does sound like him

👍️ 1

mrmainstreet 12 hours ago

Interesting. I use GoodRx all the time and it's legit.

👍️0

seve333 12 hours ago

I remember how hyped up Brave was on here a year ago and hyped for a long time. I never understood the hype people were acting like it was going to be huge and drive the stock to 50 bucks. Some said Denner knew what he had in Brave. I think it is safe to say at this point Denner doesn't and never had any secret weapon or master plan. He is doing the exact same thing the old management did to a T. I guess maybe he is a little better at controlling costs but other than that there are no differences that I see. It makes you wonder what the point of the nasty proxy battle even was for especially given we get even less communication from denner.

👍️0

JRoon71 13 hours ago

Noticed that as well. Again, this is why we need RW data. Man, I wish MITIGATE gave us something.

👍️0

CaptBeer 13 hours ago

With all the talk about IPE and an AFib adverse side effect, I found it interesting that in this study there were 2 AFib events, both of which occurred in the placebo arm.

👍️ 2

JRoon71 13 hours ago

Monk, what are you asking? There was essentially no difference between Vascepa and placebo. In fact, the placebo group actually did slightly better (which was not statistically significant).

IMO, the trial is too short, and I'm not even sure the outcome measures were appropriate. But in a short trial like this, it's all they could really measure.

As CaptBeer stated, I believe that EPA is effective over long periods of time, which is why populations with high fish intake have lower incidence of dementia. Vascepa is not an acute medication.

But outside of meta-analysis, I don't believe a long-term trial could ever be conducted like this. It would have to be VERY long, and it would have to start earlier in life.

👍️0

JRoon71 13 hours ago

Monk, couple things:

1. The report is not "final". The NLM does a review process on the submission, with comments. But they are required to publicly post the submission within 30 days of original submission, even if all questions have not yet been answered. You can see their comments in the results tab. So, nobody would likely "announce" results until the submission was "final".

2. This is not Amarin's study. So since the results didn't say anything positive, Amarin has zero reason to PR this. Same with U of Wisc. No need to make a major announcement.

3. The results are not "buried". They are displayed exactly how the NLM requires it to be displayed. They have a standard format that all trials follow.

👍️0

CaptBeer 13 hours ago

the differences between V and the placebo were not significant. That’s not to say that IPE isn’t beneficial in the long run ( really long, like 10 years), but it does say that no one will be doing a study like that any time soon. I’ve been on VASCEPA for 10 years now and I’m still doing fine.

👍️ 1

DMC8 14 hours ago

https://clinicaltrials.gov/study/NCT02719327?tab=history&a=17#version-content-panel

👍️0

Monk4444 1 day ago

Capt. B.
Your thoughts on this report from Jroon that Brave was a bust???

👍️0

Monk4444 1 day ago

Rose, Roon
Something does not seem right here.
Why do you have to dig for the results?
I thought this would be more of an "announcement"
than a technical piece with results buried??

👍️0

rosemountbomber 1 day ago

Thanks for posting. Good to know. Of course those with insurance would still pay less than that for GV.

👍️0

xblkbk 1 day ago

BbI,

Don’t know if this has already been posted, but GoodRx is saying switch from generic V to brand V for less money!!!

Per their “exclusive manufacturer discount”:

30 day, branded V, retailing for $406.65, is $98.40 with GoodRx

90 day, retailing for $1216, is $295.20 with GoodRx

I know management had talked in the past about the problem that an USA authorized generic’s pricing would disadvantage reimbursement negotiations in the EU. So maybe this “exclusive discount” is a backdoor for the near term??

My script is up for renewal in a few days. Since I’m stuck on Obamacare, where V isn’t covered, I’ve been paying $680 for a 90 day supply with the current Amarin discount. Will use the GoodRx codes and see if they work!!!

👍️ 3

rosemountbomber 1 day ago

You have to expand those results sections to see it.

👍️0

north40000 1 day ago

Meantime, take a look at bfiest’s latest message on the CDMO ticker symbol, and the Biosecure Act summary discussion there. If that bill passes the Senate and is signed into law, Medicare ability, VA hospital ability to contract with foreign jurisdiction producers of meds/drugs may be affected. What effect on Hikma, Dr.Reddy et al? Do they already produce their generic for Vascepa in the United States, or do they import from abroad…..?

👍️0

Monk4444 1 day ago

JR
Could not find any of this verbiage.
"The average ASL at 18 months for the IPE group was slightly lower than the placebo group, but this difference did not reach significance.

On average, there was a slight increase in pTau181 in CSF after 18 months of IPE compared to placebo after controlling for age at baseline Visit and pTau181."

👍️0

north40000 1 day ago

Thanks for summary. I’ll try what you suggest……just back from workout with physical trainer.

👍️0

seve333 1 day ago

Yep but pretty concerning when denner could have had berg the whole time he picked his own guy who did not even last a year. I know denner was really hyped up but I have seen nothing to impress me about him. I remember when they said denner would never ever let the stock drop below a buck and was going to sell this for 15 a share. Now here we are. I would say it cant get any worse but it always can with AMRN. The biggest issue is nobody even knows what denners plan is he has never said a word.

👍️0

rosemountbomber 1 day ago

Unfortunately I am not as confident. What I can’t understand is how someone who should know his way around the stock market could possible authorize or pursue a RS, if indeed that is what actually happens. A RS split is not negative only when a company has positive and growing earnings. Otherwise the loss per share gets magnified and the market drives the stock price back from whence it came prior to RS.

But I appreciate your post as it gives me a glimmer of hope that the nonsense of a RS is not undertaken.

👍️0

Birdbrain Ideas 1 day ago

You raise a very good counterpoint suggestion to my doom-and-gloom fear that they're going to announced a reverse split. The Investors Day event would make sense if they announce on earnings day at the end of the month that they are switching Vascepa to a generic in the U.S. I imagine they waited one quarter to see exactly how much their revenue dropped with the loss of that deal that brought us 25 percent of our revenues. If the loss on the quarter was substantial, it would make sense that they'd switch to a generic and say at earnings time that they're staging an Investor Day in a few weeks to better educate investors on what this will mean for Amarin going forward.

Actually, as I was writing the above, I was thinking that this is a more likely purpose for the Investor Day than my Doom and Gloom scenario.

👍️ 1

rosemountbomber 1 day ago

I think price-wise we can (I believe successful AGs can still command a slightly higher price than Generics) but since the Generics have so many products and connections with the pharmacies, that I have always thought it would be tough slough.

It is the CVS Caremark decision that makes me wonder if an AG might make sense. Let me explain. CVS Caremark has stopped brand on the formulary (commercial) but although I could be wrong I believe they cover GV no matter the manufacturer. So they would automatically cover an AG. Willing yo stand corrected on this.

👍️0

JRoon71 1 day ago

Not real easy to copy and paste from this. Go to the link, scroll all the way down to Outcome Measures. Need to expand each Statistical Analysis section.

Tau and Beta Amyloid were slightly higher in the Treatment (Vascepa) Arm.

Cognitive Performance was slightly worse in Treatment (Vascepa) Arm (.455 vs. .611).

Cerebral Blood Flow was almost the same in both. Slightly higher in Treatment (Vascepa) Arm.

👍️0

north40000 1 day ago

Can you copy that portion of your link that discusses failure, and paste that discussion here? Today is 10/09…..that much I see, as well as an NIH comment that yields nothing on attempts to click.

👍️0

JRoon71 1 day ago

I posted the link. Not sure what else to tell you. Did the link not work?

👍️0

north40000 1 day ago

Where is your link to BRAVE trial failure? I see no evidence of failure from the link you posted a few hours earlier today.

👍️0

W0lf1 1 day ago

RMB, thank you for your reply. Can we compete with the generics by offering generic versions of Vascepa?

👍️0

rosemountbomber 1 day ago

Many times I am obviously too dumb to think of or anticipate developments with this stock but if I had to come up with something I would say this.

Here in the US there would have to be some legal victories, or possibly the introduction of an AG. Could there be some deal or arrangement with a statin mfr to market a combo?

Outside of the US it seems more reimbursement approvals and an acceleration of scripts in ROW would be a welcome positive.

👍️0

KnowNothingJonSnow 1 day ago

I’m old enough to remember when we had $700m in cash not all that long ago. Seems to be dwindling fast.

👍️0

JRoon71 1 day ago

BB, it was a biomarker study, so age shouldn’t have mattered much ( other than possibly the cognitive assessment).

But EPA is not an acute medication. It’s quite possible that over long periods of time, it can prevent buildup of tau and BA, to a degree.

This is why populations with high fish intake have lower incidence of Dementia.

👍️ 1

Birdbrain Ideas 1 day ago

I agree completely. The parameters of the trial seemed off base as well. I guess they kept extending the end date of the trial hoping something would show up. When I saw the age of the participants, I was thinking it was catching them too early for much of anything to show up unless you're dealing with someone with early onset of symptoms.

👍️0

W0lf1 1 day ago

Are there scenarios that would realistically lead to a favorable outcome?

👍️0

Number sleven 1 day ago

RMB, If Amarin were marketing Vascepa in China on their own I might share your concerns. Our partner, a Chinese company, is selling the product. The Chinese government has certain self serving motivations to defend that company.
Sleven,

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Amarin Corp PLC (AMRN)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

AMRN News

Amarin Announces Two Upcoming Investor Events

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

Form 8-K - Current report

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

Form 8-K - Current report

Amarin Board of Directors Announces CEO Transition

AMRN Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Amarin Corp PLC (AMRN) News

Amarin Corp PLC (AMRN)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

AMRN News

Amarin Announces Two Upcoming Investor Events

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

Form 8-K - Current report

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

Form 8-K - Current report

Amarin Board of Directors Announces CEO Transition

AMRN Discussion

Your Recent History

Company

Business

Popular

Get The App